Retatrutide, a novel dual stimulator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising data in early patient studies. Recent inquiry https://indexedbookmarks.com/story21277060/retatrutide-emerging-studies-and-possible-therapeutic-uses